Large Cap
Drug Manufacturers - Specialty & Generic
Stocks Ranked by
Market Capitalization
| # | Name | Market cap | Price |
Price change % |
|
|---|---|---|---|---|---|
| 1 |
1
Takeda Pharmaceutical
TAK
$69.1B
| $69.1B | $21.64 | 0.23% |
|
| 2 |
2
Teva Pharmaceutical Industries
TEVA
$49.7B
| $49.7B | $42.62 | 0.12% |
|
| 3 |
3
Haleon
HLN
$39.7B
| $39.7B | $9.05 | 1.63% |
|
| 4 |
4
Zoetis
ZTS
$33.9B
| $33.9B | $83.48 | 1.08% |
|
| 5 |
5
United Therapeutics
UTHR
$24.9B
| $24.9B | $584.10 | 0.64% |
|
| 6 |
6
Viatris
VTRS
$23.4B
| $23.4B | $20.45 | 1.4% |
|
| 7 |
7
Neurocrine Biosciences
NBIX
$16.8B
| $16.8B | $165.92 | 0.37% |
|
| 8 |
8
Elanco Animal Health
ELAN
$12.9B
| $12.9B | $25.85 | 2.12% |
|
| 9 |
9
Dr. Reddy's Laboratories
RDY
$12.3B
| $12.3B | $14.79 | 0.61% |
|
Large Cap Drug Manufacturers - Specialty & Generic Stocks at a Glance
Specialty and generic drug manufacturers develop branded niche therapies, off-patent generics, and animal-health and cannabis products. Generics compete on price and manufacturing scale, while specialty brands carry pharma-like margins on smaller markets.
There are 9 large cap Drug Manufacturers - Specialty & Generic stocks — companies in the Drug Manufacturers - Specialty & Generic industry with a market cap between $10B and $200B — worth a combined $283B.
The largest by market cap are Takeda Pharmaceutical (TAK) at $69.1B, Teva Pharmaceutical Industries (TEVA) at $49.7B and Haleon (HLN) at $39.7B.
Among institutional investors, Takeda Pharmaceutical (TAK) drew the most net new fund positions in Q3 2026: 66 funds opened new positions, taking total fund holders up 13 (3.4%) quarter-over-quarter.
- Combined market cap: $283B across 9 stocks.
- Large Cap: market cap between $10B and $200B.
- Largest constituent: Takeda Pharmaceutical (TAK), $69.1B market cap.
- Most net new fund positions in Q3 2026: Takeda Pharmaceutical (TAK), +13 holders.
Market caps and prices updated daily; fund activity based on aggregated SEC 13F filings for Q3 2026.